Information Provided By:
Fly News Breaks for April 17, 2015
MNTA
Apr 17, 2015 | 07:46 EDT
Brean Capital raised its price target on Momenta to $25 from $15 following yesterday's announcement of the approval of generic Copaxone. Brean Capital reiterated its Buy rating on Momenta shares.
News For MNTA From the Last 2 Days
There are no results for your query MNTA